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We have previously described several receptors on the chondrocyte membrane. In an attempt to further characterize the coupling mechanisms of 
serotoninergic receptors, here we examined the involvement of serotonin in the phospholipase A2 activity. Serotonin dose-dependently stimulated 
phospholipase A2. This activation enhanced collagenase type II activity and had no effect on proteoglycanase activity. 
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1. INTRODUCTION 
Chronic progressive destruction of the articular joint 
structure is a characteristic pathological feature of 
osteoarthritis. Intra-articular elevations of inflam- 
matory mediators and tissue hydrolyzing proteases 
(collagenase and proteoglycanase) are believed to be 
responsible for this articular degeneration process 
[a,%]. The regulation of chondrocyte metabolism is 
poorly understood but the role of some agents such as 
histamine [3-61 and interleukin-1 [7] in cartilage 
degradation is now established. Stimulation of 
degradarive enzymes by chondrocytes has been sug- 
gested to be related to prostaglandin synthesis via ac- 
tivation of phospholipase A2 (PLAZ) by both 
interleirkin-1 IMI 2nd rn~rhnnir~ll trnlnqa 191. We recent- 
receptors were 
ic cartilage [ 101. 
1. lrrllu~.rice on PLA2 ac- 
ted with proteoglycanase 
arr,.*r, . 
2. MATERIALS AND METHODS 
2.1. Chondrocyte isolation and stimulation 
Human osteoarthritic cartilage was obtained from femoral heads 
or knee joints at the time of total hip or knee replacement (average 
age 64, range 56-72). At the time of surgery, each specimen was rins- 
ed with physiological saline to remove blood and full depth cartilage 
was excised aseptically and used immediately. Articular chondrocytes 
were isolated by sequential enzymatic digestion (trypsin and col- 
lagenase) of cartilage slices as described [ 11,121. The cells were wash- 
ed twice with DMEM medium to eliminate collagenase (no 
collagenolytic activity was found in the last supernatant). The chon- 
drocytes were seeded (4 x lO’/well) into 24-well microtiter plates and 
treated in an incubator at 37’C (atmosphere of 95% air, 5% COz) for 
60 min with different compounds which were added to the DMEM 
media. 
2.2. Preporation of enzymatic fraction 
The chondrocytes were resuspended in 20 mmol/l Tris-HCl buffer, 
pH 7.40 (lo6 cells/ml buffer). Cells were homogenized with a Potter- 
Elvehjem and broken up by ultrasonic treatment in ice with a probe 
(Sonimass type 25 T, 120 V, 4 x 30 s). The homogenate was used for 
enzymatic determinations. In acellular experiment systems, com- 
pounds were added to the chondrocyte homogenate during enzymatic 
kinetics. 
2.3. Assay for PLA2 activity 
The assay was performed using the method of Higuchi et al. [13] 
with some modifications [14]. Unlabelled L-cr-phosphatidylethanol- 
amine and labelled l-palmitoyl-2-[14C]-linoleyl-L-3-phosphatidyl- 
ethanolamine were employed as substrates. 
2.4. Asmy for collagenolytic activity 
Collagenolytic activity was determined using [‘Hlacetylated solu- 
ble type 11 collagen as a substrate (141. Collagen was [‘Hlacetylated 
with i3H]acetic anhydride 1151. Using polyacrylamide gel elec- 
!rop!?oresis the labe!!ed co!lage~ molecules 1 degradaicd ‘oy thou- 
drocyte homogenate and a pure collagenase were found to be similar, 
while pronase digestion gave different products. 
2.5. Assay for proteoglycanase activity 
Proteoglycans extracted from normal human articular cartilage 
1141 were i3H]acetylated [15]. Proteoglycanase was measured by the 
release of soluble radioactive fragments from labelled proteoglycans 
1141. No radioactivity was released by a specific chemical desacelyla- 
tion of glycosaminoglycans from labelled proteoglycans. The 
measured radioactivity was thus specific to the proteoglycan core 
protein degradation. 
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Table II 
Effects of PLA2 inhibitors in acellular systems on PLAZ, coliagenase 
and proteoglycanase activities 
Addition PLA2 Collagenase Proteo- 
glycanase 
None 100 100 100 
Mepacrine 110 f 15 110 f 35 120 + 45 
p_Bromophenacyl 
bromide 15 jz 15 94 + 20 105 zt 30 
The concentrations of additions were 15 pmol/l; compounds were 
added to the chondrocyte homogenate during enzymatic kinetics. The 
data are the means * SD from five experiments, each assayed in 
triplicate. Results are expressed as a percentage in relation to controls 
drocyte homogenate (acellular systems) not in’ cell 
medium, only PLAZ was decreased with BPB 
(Table II). Collagenase and proteoglycanase activities 
were unmodified. 
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emol/l 
Fig. 1, Dose-response relationship between serotonin concentration 
4. DISCUSSION 
and PLA2 activity. Serotonin is known to be a mediator of inflamma- 
tion. We have previously shown that, human osteoar- 
thritic articular chondrocytes possess serotoninergic 
3. RESULTS receptors [lo]. The results presented herein show, for 
Serotonin stimulated PLAZ activity in a concentra- 
the first time to our knowledge that human osteoar- 
tion-related manner with concentrations as low as 
thritic articular chondrocytes have a pathway for 
1 pmol/l causing a significant increase above control 
serotoninergic receptor-mediated activation of PLA2 
(Fig. 1). The response appeared to be maximal (X 6) by 
and collagenase. The following findings suggest his af- 
I5 ymol/l. 
firmation: 
Treatment of chondrocytes with 15 pmol/l serotonin 
(i) serotonin-stimulated PLA2 and collagenase ac- 
stirnulated PLA2 ( x 6) and collagenase (x 4) activities. 
tivities were inhibited by the addition of mianserin, a 
Serotonin-stimulated PLA2 and sollagenase activities 
serotoninergic antagonist [ 171. 
were decreased by mianserin, mepacrine and p- 
(ii) BPB and mepacrine have been identified as in- 
bromophenacyl bromide (BPB) (Table I). No com- 
hibitors of PLA:!. BPB covalently ‘modifies essential 
histidine residues associated with’ the catalytic site on 
pound had any effect on the proteoglycanase activity. 
When mepacrine and BPB were introduced in chon- 
the enzyme [l$]. Mepacrine has been shown to inhibit 
PLA2 activity in cells but not in acellular systems by 
altering the calcium availability to the enzyme 1191. 
These compounds decreased collagenase activity in cell 
Table I experiments but did not affect this activity in acellular 
Effects of chondrocyte treatments on PLAf, collagenase and experiments, although BPB remained a PLAZ in- 
proteoglycanase activities hibitor. This last finding suggests that collagenase ac- 
- tivation was related to serotonin stimulation via PLAZ 
addition PLA2 Collagenase Proteo- activation. 
glycanase The chondrocyte mechanisms involved in the coupl- 
None 100 100 100 ing of serotonin receptor interaction with PLAZ activa- 
Serotonin 612 f 73 405 f 81 150 f 64 tion are completely unknown. PLA2 is thought to play 
+ Mianserin 158 f 52 126 + 54 115 f 35 a central role in providing arachidonic acid for subse- 
+ Mepacrine 30 & 12 35* 15 93 f 42 
+p-Bromophenacyl 
quent metabolism to prostaglandin and leucotrienes, 
bromide 25 f 20 30 f 10 84 f 32 
potent lipid mediators of inflammation. PLA2 regula- 
tion was studied in different models: rabbit platelets 
The concentrations f additions were I§ pmol/l; compounds were with histamine [20], glomerular mesangial cells with 
added 10’ the chondrocytes for 60 min after which the medium was 
removed and the cells assayed for enzymatic determinations. The 
epidermal growth factor [%l] and macroghage cell line 
data are the means I SD from 6 experiments, each assayed in with calcium [22]. Wistamine and epidermal growth 
triplicate. Results are expressed as a percentage in relation to controls factor enhance PLA2 activity. Chondrocyte PLA2 ac- 
39 
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tivation has been described.directly with cytokines 171 [7] Gilman, S.C. (1987) J. Rheumatol. 14, 1002-1007. 
and indirectly with histamine [23]. The latter shows in- [S] Chang, J., Gilman, SC. and Lewis, A.J. (1986) J. Immunol. 
creased prostaglandin E production with 331 receptor 136, 1283-1287. 
stimulation while the former shows that interleukin-1 
[9] Chrisman, O.D., Ladenbauer-Bellis, J.M. and Panjabi, M. 
(1981) Clin. Orthop. 161, 275-284. 
induced PLA2 activation, prostaglandin E2 synthesis [lo] V&non, E., Broquet. P., Mathieu, P.. Louisot, P. and 
and latent neutral protease secretion in rabbit articular Richard, M. (1990) Biochem. Int. 20, 251-255. 
chondrocytes. Our resu!ts are similar and lead to the fll] Green, W.T. (1971) Clin. Orthop. 75, 248-260. 
suggestion that serotoninergic receptor-mediated ac- [12] Kaniak, J., Moskatewski, S. and Darlynkiewicz, 2. (1965) Exp. 
tivation of PLA2 induced prostaglandin EZ synthesis 
Cell. Res. 39, 59-63. 
113) Higuchi, H., Uchida, S., Matsumoto, K. and Yoshida, H. 
which activates collagenoiytic activity. (1983) Eur. J. Pbarmacol. 94, 229-239. 
1141 Vi&non, E., Mathieu, P., Lot&sot, P., Vilamitjana, J., 
Harmand, M.F. and Richard, M. (19S9) J. Rheumatol. 16, 
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